Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elite sport and development of asthma: Airway inflammation and treatment
2005-003142-34Phase 4Terminated
- Sponsor
- Respiratory and Allergy Research Unit
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of salmeterol + fluticasone in asthma and exercise-induced bronchospasm (EIB) (2 arms), sponsored by Respiratory and Allergy Research Unit. Primary endpoint: Reduced airway inflammation measured by exhaled nitric oxide. Started Aug 2005; status: terminated.
02
Drugs
salmeterol + fluticasone
03
Conditions
asthmaexercise-induced bronchospasm (EIB)
Beyond the preview
Go deeper on 2005-003142-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003142-34.